For most people living with chronic hepatitis B, treatment means a daily antiviral with no end date. Health Canada has just approved the first drug designed to change that, and for a portion of patients, it could mean stopping treatment altogether.
On November 3, Health Canada approved bepirovirsen, sold as Hibsago, as the first therapy in Canada meant to achieve a functional cure of chronic hepatitis B, GSK announced. The company expects supply to reach eligible patients in early 2027. It is a genuine step forward, though it will help a fairly small group, and many Canadians who could benefit do not yet know they have the virus.
Key takeaways
Bepirovirsen is a six-month course added to standard antiviral treatment.
In phase 3 trials, 19 percent of eligible adults reached a functional cure, and 26 percent of those with the lowest antigen levels did, compared with none on placebo.
It is approved only for adults without cirrhosis whose virus is already well controlled and whose antigen levels are low.
An estimated 262,000 people in Canada live with chronic hepatitis B, and about half do not know it, according to CBC News.
Do not stop your current antiviral on your own while you wait for the new option.
What does a functional cure mean?
Hepatitis B is a virus that infects the liver, and a long-term infection can lead to scarring and liver cancer. Today's antivirals keep the virus suppressed but rarely clear it, so many people stay on them for life, and they produce a functional cure in only about one percent of patients.
A functional cure does not mean the virus is gone from your body completely. It means the virus's genetic material and a key protein, the hepatitis B surface antigen, stay undetectable in the blood for at least 24 weeks after all treatment stops. That is a sign your immune system is keeping the infection in check on its own.
The B-Well trials added a six-month course of the new hepatitis B drug to standard treatment. It produced a functional cure in 19 percent of adults with lower antigen levels and 26 percent of those with the lowest levels. No one in the placebo group reached it. That is a big jump from one percent, but it also means most people who take it will not be cured.

Who is eligible for the new drug?
Health Canada approved the hepatitis B drug for a specific group. You need to be an adult without cirrhosis who has been on standard antiviral treatment for at least six months, with the virus well suppressed and surface antigen levels below a set threshold. The U.S. Food and Drug Administration set similar limits when it approved the drug in October.
Experts have raised fair questions about how long the effect lasts beyond the trial period and how many people will actually qualify. If you are not eligible, standard antivirals still work well at keeping the virus under control and protecting your liver, which matters because liver health also depends on other factors, as our guide to fatty liver disease explains.
How soon can you get it and what will it cost?
GSK expects the hepatitis B drug to reach Canadian patients in early 2027. The cost and public coverage have not been announced, and those questions will decide how many eligible people can actually use it. Access to a liver specialist can also be a bottleneck, as our report on the wait for hepatitis B testing and liver care in Calgary showed.
Should you get tested?
With about half of infected Canadians unaware, a blood test is the only way to know where you stand. Our guide to which common infections are worth getting tested for explains who should ask.
Ask for a blood test. If you have never been tested for hepatitis B, or are not sure, ask at your next appointment, especially if you were born where the virus is common.
Check your vaccination. Many adults born before routine school vaccination may not be protected, and the vaccine is also advised for some travellers, as our guide to health risks Canadians face when travelling notes.
Ask whether you could qualify. If you already live with hepatitis B, ask your doctor or liver specialist whether your results might make you a candidate in 2027.
Keep taking your current treatment. Stopping an antiviral on your own can cause a dangerous flare of the infection.
Frequently asked questions
Is bepirovirsen a full cure?
Bepirovirsen aims for a functional cure, which means the virus stays undetectable in the blood for at least 24 weeks after all treatment stops. The virus is not completely removed from the body. In the trials, about one in five eligible adults reached a functional cure, so most people who take it will still need ongoing monitoring.
Who can get the new treatment?
Health Canada approved it for adults without cirrhosis who have been on standard antivirals for at least six months, have a well-suppressed virus, and have surface antigen levels below a set threshold. Your liver specialist can check your recent blood work to see whether you might qualify once supply arrives in early 2027.
How do I find out if I have the virus?
A simple blood test shows whether you have hepatitis B now, had it in the past, or are protected by vaccination. Many people with chronic infection have no symptoms for years, which is why about half do not know. Ask your family doctor or a walk-in clinic for testing, especially if you have never been checked.
Your next step
If you want to get tested or talk through your treatment options, a family doctor can order the blood work and refer you to a liver specialist if needed. The Medimap Health Hub has more on infections and testing, and you can book a family doctor near you.
Disclaimer: This article is for general information only and is not medical advice. It does not replace a conversation with a doctor or other qualified health professional who knows your history. If you think you are having a medical emergency, call 911 or go to the nearest emergency department.
Find an allergy or specialist clinic near you? Search through Medimap — no referral needed.
Search clinics →
